Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Development. Author manuscript; available in PMC 2010 March 1.
Published in final edited form as:
PMCID: PMC2685950

EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis


Heterozygous loss of Twist1 function causes coronal synostosis in both mice and humans. We showed previously that in mice this phenotype is associated with a defect in the neural crest-mesoderm boundary within the coronal suture, as well as with a reduction in the expression of ephrin A2 (Efna2), ephrin A4 (Efna4) and EphA4 in the coronal suture. We also demonstrated that mutations in human EFNA4 are a cause of non-syndromic coronal synostosis. Here we investigate the cellular mechanisms by which Twist1, acting through Eph-ephrin signaling, regulates coronal suture development. We show that EphA4 mutant mice exhibit defects in the coronal suture and neural crest-mesoderm boundary that phenocopy those of Twist1+/− mice. Further, we demonstrate that Twist1 and EphA4 interact genetically: EphA4 expression in the coronal suture is reduced in Twist1 mutants, and compound Twist1-EphA4 heterozygotes have suture defects of greater severity than those of individual heterozygotes. Thus, EphA4 is a Twist1 effector in coronal suture development. Finally, by DiI labeling of migratory osteogenic precursor cells that contribute to the frontal and parietal bones, we show that Twist1 and EphA4 are required for the exclusion of such cells from the coronal suture. We suggest that the failure of this process in Twist1 and EphA4 mutants is the cause of craniosynostosis.

Keywords: EphA4, Twist1, Boundary formation, Cell guidance, Craniosynostosis


The patterned growth of organ rudiments depends on the close regulation of cell proliferation, differentiation and migration. Defining the contributions of these processes is key to understanding how pattern is established, and how developmental anomalies arise. Here we address the cellular mechanisms that control the growth of the mammalian skull vault, as well as the mechanisms underlying craniosynostosis, the premature fusion of the calvarial bones.

The mammalian skull vault is a composite structure, consisting of membrane bones with distinct lineage origins (Jiang et al., 2002). The frontal bones and the central portion of the interparietal bone are derived from neural crest, the parietal bones and the lateral portion of the interparietal bone from paraxial mesoderm. The bones of the skull vault are separated by sutures, fibrous joints that accommodate the expanding brain and allow the skull to undergo reshaping during birth. Craniosynostosis, the premature fusion of calvarial bones at the sutures, occurs as frequently as 1 in 2500 live births. Affected individuals have abnormally shaped skulls, and in some instances mental retardation and impaired vision and hearing (Cohen and MacLean, 1999; Wilkie and Morriss-Kay, 2001).

Mutations in a number of genes, collectively functioning in several signaling pathways, can cause craniosynostosis in humans or mice (Ornitz and Marie, 2002; Rawlins and Opperman, 2008; Wilkie, 1997). Among these genes are TWIST1, which regulates both BMP and FGF signaling (Carver et al., 2002; Connerney et al., 2008; el Ghouzzi et al., 1997; Howard et al., 1997; Rice et al., 2000; Rice et al., 1999; Wilkie, 1997), FGFR1, FGFR2 and FGFR3 (Jabs et al., 1994; Marie et al., 2005; Meyers et al., 1995; Yu et al., 2003), the Wnt pathway inhibitor, Axin2 (Yu et al., 2005), the Bmp target, MSX2 (Jabs et al., 1993), and RAB23, a component of the Shh pathway (Jenkins et al., 2007). The cellular mechanisms underlying craniosynostosis have been investigated using both mouse and tissue culture models (Maxson and Ishii, 2008; Rawlins and Opperman, 2008; Wilkie and Morriss-Kay, 2001). Mice carrying the S252W or P253R mutation engineered into Fgfr2 mimic features of Apert syndrome (Wang et al., 2005; Yin et al., 2008), and exhibit enhanced RTK signaling (Shukla et al., 2007). Activation of Wnt signaling by targeted deletion of Axin2 results in an expansion of the pool of osteoprogenitors and ultimately to synostosis (Liu et al., 2007; Yu et al., 2005). Although details of underlying developmental mechanisms that lead ultimately to synostosis are still lacking, one reasonable hypothesis is that it is caused by changes in the balance of proliferation and differentiation of osteogenic cells in the developing suture (Bialek et al., 2004; Chen et al., 2003; Lee et al., 1999; Yousfi et al., 2002; Yousfi et al., 2001).

Our recent results on the mechanism of Saethre-Chotzen syndrome, caused by heterozygous loss of function of Twist1, draw attention to the significance of tissue boundaries in the development of synostosis (Merrill et al., 2006). Individuals affected with Saethre-Chotzen have coronal synostosis, fusion of the frontal and parietal bones at the coronal suture. Twist1 mutant mice also exhibit coronal synostosis (Carver et al., 2002; el Ghouzzi et al., 1997). In such mice and in cultured osteoblasts, Twist1 can inhibit osteoblast differentiation by regulating the activity of Runx2 (Bialek et al., 2004; Guenou et al., 2005; Yoshida et al., 2005). Connerney et al. have presented evidence that reduced dosage of Twist1 changes the proportion of Twist1 homo- and heterodimers within developing sutures and thereby regulates suture patency (Connerney et al., 2008; Connerney et al., 2006). We demonstrated that Twist1 mutant mice have a deficiency in the neural crest-mesoderm boundary at the coronal suture (Merrill et al., 2006). The boundary normally lies between the mesoderm-derived cells of the prospective suture and the neural-crest-derived osteogenic cells of the prospective frontal bone (Merrill et al., 2006; Yoshida et al., 2008). Thus the boundary not only demarcates neural crest and mesoderm, but also osteogenic and non-osteogenic sutural cells. In Twist1 mutants, neural crest cells crossed the boundary into the mesoderm domain of the suture (Merrill et al., 2006).

We showed previously that the change in cell behavior at this boundary was associated with a reduction in the levels of the ephrin ligands, ephrin A2 (Efna2) and ephrin A4 (Efna4), as well as their receptor, EphA4. Moreover, we identified loss-of-function mutations in EFNA4 in 3/77 patients (Merrill et al., 2006). Ephrins are membrane-bound ligands that interact with Eph receptors, a large family of receptor tyrosine kinases (Klein, 2004; Kullander and Klein, 2002; Wilkinson, 2001). Ephrin-Eph signaling is bidirectional, through both the receptor and the ligand. Engagement of Eph receptors by membrane-bound ephrin ligands induces dimerization and subsequent trans-phosphorylation of the receptors, leading to changes in the activity of downstream effectors, which include the mitogen-activated protein kinases ERK, c-Jun N-terminal kinase, Src family kinases and Ras/Rho family GTPases. Ephrin-Eph signaling regulates a variety of developmental processes including vascular and neuronal development and the establishment of developmental boundaries (Klein, 2004; Kullander and Klein, 2002; Martinez and Soriano, 2005; Palmer and Klein, 2003; Pasquale, 2005; Poliakov et al., 2004; Surawska et al., 2004).

Here we test for a causal connection between Twist1, ephrin A signaling and craniosynostosis; we also investigate cellular mechanisms controlled by ephrin A signaling in the developing skull vault. We demonstrate that loss of function of the Efna4 receptor, EphA4, causes coronal synostosis in mice, definitively establishing the link between craniosynostosis and loss of ephrin A signaling suggested by our earlier human genetic findings (Merrill et al., 2006). We show further that EphA4 interacts genetically with Twist1 and acts as a Twist1 effector in the control of the frontal-parietal boundary and in the regulation of the RTK indicator, P-Erk1/2 and the BMP pathway indicator, P-Smad1/5/8. Finally we use 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI) labeling to show that Twist1 and EphA4 control the guidance of migratory osteogenic cells to the leading edges of the growing frontal and parietal bones, and that these genes are required to exclude such osteogenic cells from the coronal suture. Our results suggest that migration of osteogenic cells is an important element in the patterned growth of calvarial bones, and that the mis-migration of such cells plays a crucial role in the development of craniosynostosis in Twist1 and EphA4 mutant mice.

Materials and Methods

Mouse mutants and genotyping

The EphA4 mutant mouse was a kind gift of Elena Pasquale; the Efna2 mutant, of David Feldheim. Both mutant lines were maintained in a C57Bl/6 background. The Twist1 (Chen and Behringer, 1995), R26R (Soriano, 1999), Wnt1-cre (Danielian et al., 1998) and Mesp1-cre (Saga et al., 1999) alleles have been described. We genotyped EphA4, Efna2, Twist1, R26R, Wnt1-cre and Mesp1-cre alleles by PCR as described (Chen and Behringer, 1995; Dottori et al., 1998; Feldheim et al., 2000; Jiang et al., 2002; Saga et al., 1999).

Histology, immunostaining and in situ hybridization

Heads of embryos were embedded in OCT medium (Histoprep, Fisher Scientific) before sectioning. Frozen sections were cut at 10 μm. Analysis of β-galactosidase activity of Wnt1-Cre/R26R and Mesp1-Cre/R26R reporter gene expression was carried out as described (Ishii et al., 2003). Immunostaining of frozen sections was largely carried out as previously reported (Ishii et al., 2003). Immunohistochemistry was performed using rabbit anti-Runx2 (Sigma), rabbit P-Erk1/2 (Cell Signaling), rabbit Erk1/2 (Cell Signaling) and rabbit anti-P-Smad1/5/8 (Cell Signaling) diluted in 1% BSA/PBS and incubated overnight at 4°C. Detection of primary antibody of anti-Runx2, anti-P-Erk1/2 and anti-Erk1/2 was performed by incubating goat anti-rabbit-HRP (Zymed, 1/250) for 1 hour at room temperature and visualizing with DAB substrate. Detection of anti-P-Smad1/5/8 was performed by incubating rhodamine-labeled goat anti-rabbit IgG (1:100) for 1 hour at room temperature followed by DAPI counterstaining and examination by epifluorescence microscopy. Non-radioactive section in situ hybridization using the tyramide signal amplification (TSA) method was performed as described (Adams, 1992; Paratore et al., 1999; Yang et al., 1999). Briefly, to analyze mRNA expression by TSA, DIG-labeled or FL-labeled riboprobes were allowed to hybridize with the section and were detected with anti-DIG or anti-FL antibodies conjugated to horseradish peroxidase (POD). Indirect TSA fluorescence system (TSA-biotin/avidin-FITC) was used to detect the POD-conjugated antibody (Perkin Elmer). RNA probes were generated as reported: EphA4 (Nieto et al., 1992), Twist1 (Rice et al., 2000).

Whole-mount skull Alizarin Red S staining

Skulls from 21-day-old postnatal mice were stained for bone with 2% Alizarin Red S in 1% KOH for 1 to 2 days. The specimens were then cleared and stored in 100% glycerol.

Whole-mount alkaline phosphatase (ALP) staining

Whole-mount staining for alkaline phosphatase was carried out as described (Ishii et al., 2003). Embryonic day 13.5 (E13.5) embryo heads were fixed in 4% paraformaldehyde in PBS, and were bisected midsagitally after fixation. Presumptive calvarial bones were stained with NBT and BCIP (Roche).

Exo utero DiI labeling of migratory osteogenic precursor cells

Details of the exo utero manipulation have been described (Muneoka et al., 1986; Serbedzija et al., 1992). Briefly, E13.5 embryos with embryonic membranes were carefully exposed by incising the uterine wall. Two embryos from each side of the uterine horns were designated as the experimental group, and all others were removed. DiI (Molecular Probes, 1:10 dilution from 0.5% stock solution) was injected into the area of the calvarial bone rudiments under a dissecting microscope with a microelectrode (tip diameter, 20 μm) attached to a mouth pipette (Yoshida, 2005). After injection, the embryos were returned to the peritoneal cavity of dams and allowed to continue development exo utero. After 2-3 days of additional development, the embryos were removed and examined by epifluorescence microscopy. The survival rate of the embryos after DiI injection was greater than 70%.


Loss of EphA4 function causes coronal synostosis and defective formation of the neural crest-mesoderm boundary at the coronal suture

We first examined the morphology of coronal sutures in individual EphA4−/− and Efna2−/− mutant mice (an Efna4 mutant was not available). In addition, because ephrins can function redundantly with their receptors (Wang et al., 1999), we assessed compound EphA4−/−; Efna2+/− mutant mice. Alizarin-Red staining of skulls of EphA4−/− mice at P21 revealed that the coronal sutures were partially fused, a phenotype that closely resembles that of Twist1+/− mice (Fig. 1). Efna2−/− mutants exhibited normal coronal suture development. EphA4−/−; Efna2+/− double mutant skulls had no significant increase in the severity of the synostosis phenotype over EphA4−/− mutants (Fig. 1; data not shown), indicating that EphA4 plays a more prominent role than Efna2 in coronal synostosis, at least in the mouse. We therefore concentrated on EphA4 mutants in further efforts to understand the relationship between Twist1, ephrin signaling and craniosynostosis.

Fig. 1
Fusion of coronal sutures in EphA4 mutant mice

We examined the activity of alkaline phosphatase (ALP), an early osteoblast marker, in EphA4−/− embryos at E14.5 when a loss of integrity of the boundary between ALP and non ALP-expressing cells is first apparent in Twist1 mutants (Merrill et al., 2006) (Fig. 2). In wild-type embryos, the prospective coronal suture is evident as a layer of non-ALP-expressing cells located between the prospective frontal and parietal bones. In EphA4−/− mutants this layer exhibited a disorganized appearance and was filled with ALP-expressing cells, as is the case in Twist1+/− mutants (Fig. 2) (Merrill et al., 2006). In addition, the expression domain of ALP was substantially broader in EphA4−/− mutants, similar to a phenotype observed in Twist1 mutants.

Fig. 2
Increased number of alkaline phosphatase-expressing cells and defect in the neural crest-mesoderm boundary in coronal sutures of EphA4−/− embryos

In parallel, we assessed the status of the neural crest-mesoderm boundary by means of the Wnt1-Cre; R26R neural-crest-lineage marking system (Jiang et al., 2002) (Fig. 2). We carried out intercrosses between EphA4 mutants and embryos carrying Wnt1-Cre and R26R and examined embryos at a series of developmental stages. In EphA4−/− mutants, lacZ-positive cells were evident outside the neural crest domain. This phenotype was first detectable at E14.5 and became more severe at E16.5. We did not detect a boundary defect in heterozygous mutants. These results suggest that reduced EphA4 function results in a set of phenotypes in the coronal suture that resemble those of Twist1 mutants.

EphA4 is a downstream effector of Twist1 in the coronal suture

We sought to determine whether levels of EphA4 transcripts in the developing calvarial bones and sutures are regulated by Twist1 (Fig. 3). EphA4 mRNA was localized in the periosteal layers above and below the developing frontal and parietal bones. It was also expressed in a layer of cells outside (ectocranial to) the bone layer, and broadly within the suture mesenchyme. In Twist1+/− mutants, EphA4 expression was reduced substantially in the ectocranial and periosteal layers, consistent with our previous finding that Twist1 controls the levels of EphA4 protein expression in calvarial tissues. Twist1 expression was not changed in EphA4−/− mutants.

Fig. 3
Altered expression of EphA4 mRNA in Twist1 mutant suture

If EphA4 is an effector of Twist1, then combination Twist1+/−; EphA4+/− heterozygotes should exhibit phenotypes of greater severity than individual heterozygous mutants. We crossed Twist1+/− heterozygous mice with EphA4 mutant mice and examined skulls at E13.5, E14.5 and P21 (Fig. 4; Table 1). The penetrance of craniosynostosis as assessed at P21 increased from 73 to 94% in Twist1+/−; EphA4+/− compound mutants (n=33) compared with Twist1+/− mutants (n=26); also, a larger portion of the suture was fused (50 vs 25%; P<0.005) in the compound mutants.

Fig. 4
Genetic interaction between Twist1 and EphA4
Table 1
Influence of genotype on the penetrance of craniosynostosis

Whole-mount ALP stains of embryonic heads showed that whereas at E12.5 there was no difference in the ALP expression domain between mutants and control embryos (data not shown), by E13.5 there was a substantial change (Fig. 4). In combination heterozygotes, the ALP domain expanded into the coronal suture (Fig. 4A-C). Expression of the osteoblast markers ALP and Runx2 in sections through the coronal suture revealed a significant increase in the number of osteogenic cells within the sutures of compound heterozygotes compared with individual heterozygotes. Mutants also had ectopic Runx2-positive cells in the non-osteogenic layer ectocranial to the osteogenic layer (Fig. 4D-F). These data suggest that Twist1 and EphA4 cooperatively control the number and distribution of osteogenic cells in the coronal suture and ectocranial mesenchyme.

Twist1 and EphA4 cooperatively control P-Erk1/2 and P-Smad1/5/8 activity in the developing frontal and parietal bones

As part of an effort to understand the molecular basis of the suture defects, we examined the expression of the RTK effector, P-Erk1/2 (Fig. 5), and the BMP effector, P-Smad1/5/8 (Fig. 6). Twist1 and Eph-ephrin are known to function through the RTK pathway (Guenou et al., 2005; Pratt and Kinch, 2002; Vindis et al., 2003). FGF/FGFR signaling has a well-documented role in craniosynostosis and normal suture development (Deng et al., 1996; Johnson et al., 2000; Marie et al., 2005; Rice et al., 2000; Yamaguchi and Rossant, 1995), and Twist1 has been shown to control levels of FGFR expression and P-Erk1/2 activity in sutures of late embryonic and postnatal mice (Connerney et al., 2008; Rice et al., 2000). Finally, the BMP pathway is known to be involved in the specification and differentiation of calvarial osteogenic cells (Kim et al., 1998; Ryoo et al., 2006); forced expression of the BMP antagonist noggin can prevent fusion of the sagittal suture (Warren et al., 2003).

Fig. 5
Co-regulation of Erk1/2 phosphorylation in developing coronal suture by Twist1 and EphA4
Fig. 6
Altered distribution of P-Smad1/5/8-expressing cells in coronal sutures of Twist1 and EphA4 individual and combination mutant embryos

Immunostaining of sections of E14.5 embryos showed that P-Erk1/2 was expressed in the ectocranial non-osteogenic cell layer as well as in the underlying osteogenic layer (Fig. 5). The number of P-Erk1/2-expressing cells decreased progressively in both layers as the dosages of Twist1 and EphA4 were reduced. Total Erk was unaffected in Twist1+/−; EphA4+/− mutants, demonstrating that Twist1 and EphA4 specifically regulate the distribution of cells expressing phosphorylated Erk1/2.

The distribution of P-Smad1/5/8-expressing cells was also strongly influenced by Twist1 and EphA4 (Fig. 6). Control embryos expressed P-Smad1/5/8 at a high level in the osteogenic fronts of the growing frontal and parietal bones (Fig. 6A,B). Lower levels were evident in more mature osteoblasts, distal to the leading edges. Thus, at E14.5, the highest levels of P-Smad1/5/8 activity were associated with the progenitor cells of the osteogenic fronts and lower levels with the differentiated cells of the developing bone. There was a clear boundary between domains of high and low P-Smad1/5/8 expression in the osteogenic fronts and suture. In both Twist1 and EphA4 mutants, the number of P-Smad1/5/8-expressing cells was reduced significantly in the osteogenic fronts, and the boundary between these cells and the prospective sutural cells was blurred (Fig. 6E-L). Punctate staining of P-Smad1/5/8 was evident throughout the suture. Combination mutants exhibited an even more dramatic reduction in the number of P-Smad1/5/8-positive cells in the suture (Fig. 6M,N). These data suggest that Twist1 and EphA4 together control the number and distribution of P-smad1/5/8-positive cells in the coronal suture. Further, the reduction in the number of P-Smad1/5/8-expressing cells in the suture is consistent with our finding that high levels of P-Smad1/5/8 expression are associated with undifferentiated progenitor cells in the osteogenic fronts, and lower levels with differentiating osteogenic cells within developing bone.

Twist1 and EphA4 are required for the proper partitioning of migratory osteogenic cells between osteogenic and non-osteogenic territories in the coronal suture

Wnt1-Cre/R26R analysis of Twist1+/−; EphA4+/− embryos at E16.5 (Fig. 7), as well as E14.5 and P0 (not shown), demonstrated that relative to wild type or individual heterozygotes, a larger number of neural crest cells crossed into the undifferentiated mesoderm (Fig. 7A-C′; see also Fig. 2). Complementary results came from an assessment of the mesoderm lineage by means of the pan mesoderm marker, Mesp1-Cre/R26R (Fig. 7D-F′). In control embryos, Mesp1-Cre-directed lacZ expression was the inverse of the Wnt1-Cre lacZ domain: lacZ-positive cells were evident in the parietal bone, and in the layer of cells ectocranial to the parietal and frontal bones. There was strong labeling of the non-osteogenic cells interposed between the frontal and parietal bones, i.e. the mesenchyme of the coronal suture. These results are consistent with the recent report of Yoshida et al. (Yoshida et al., 2008). In embryos with the Twist1+/−; EphA4+/− genotype, a substantial number of lacZ-positive cells were ectopically located in the neural crest territory. Thus cells derived from mesoderm, as well as neural crest, failed to respect the neural crest-mesoderm boundary between the frontal and parietal bones.

Fig. 7
Cooperative control of neural crest-mesoderm boundary at coronal suture by Twist1 and EphA4

These data raised the possibility that a contributing cause of synostosis is the replacement or dilution of non-osteogenic sutural cells with osteogenic cells from adjacent territories. To test this hypothesis further, we used DiI labeling of embryos, exo utero (Yoshida, 2005; Yoshida et al., 2008). This allowed us to examine directly the behavior of populations of migratory osteogenic cells that contribute to the frontal and parietal bones. At E12.5, the frontal and parietal bone rudiments consist of patches of osteogenic precursor cells located in the supraorbital ridge. The frontal bone rudiment is anterior to the eye, the parietal bone rudiment is posterior. Between the rudiments is the prospective coronal suture, in later stages identifiable by the absence of ALP-expressing osteogenic cells. The prospective frontal and parietal osteogenic cells can be labeled by injecting DiI into the area of the rudiments (supraorbital ridge) at E13.5 (Yoshida, 2005; Yoshida et al., 2008) (P.G.R., N.L.W. and R.E.M., unpublished observations). During subsequent development of the injected embryos, exo utero, labeled cells migrate apically, adding to the leading edge of the frontal and parietal bones.

We asked whether such migratory osteogenic cells exhibit abnormal behavior in Twist1-EphA4 mutants. We injected DiI into E13.5 Twist1+/−; EphA4+/− embryos and allowed them to develop exo utero. We then examined the embryos at E16.5 by epifluorescence microscopy. As is evident in Fig. 8, labeled cells were excluded from the area of the prospective suture in wild-type embryos. However, such cells were present in substantial numbers in the sutural space of Twist1+/−; EphA4+/− mutant embryos. In multiple repetitions of this experiment, in which DiI was injected into the frontal bone rudiment as well as the parietal bone rudiment, we obtained closely similar results (Table 2). Thus, Twist1 and EphA4 controlled the distribution of migratory osteogenic precursor cells between the non-osteogenic coronal suture and the prospective frontal and parietal bones. We also examined the distribution of migratory osteogenic precursor cells one day earlier when they are in the process of migration. In control embryos at E15.5, DiI-labeled cells were found largely in the ectocranial, EphA4-expressing layer (Fig. 8O-Q). In EphA4-Twist1 mutants, by striking contrast, labeled cells were located diffusely within and adjacent to the osteogenic layer (Fig. 8R-T). Thus Twist1 and EphA4 determined the partitioning of osteogenic precursor cells between the non-osteogenic ectocranial layer and the ALP-expressing prospective bone. Together these results suggest that Twist1 and EphA4 function in the partitioning of migratory osteogenic cells between osteogenic and non-osteogenic territories in the coronal suture.

Fig. 8
Mis-migration of osteogenic precursor cells in Twist1+/−; EphA4+/− mutant embryos
Table 2
Location of labeled cells following DiI injection into frontal or parietal bone rudiments


The proper guidance of migratory cells is crucial for a large variety of developmental processes. Here we provide evidence that ephrin-Eph signaling, under the control of Twist1, is required to exclude migratory osteogenic cells from normally non-osteogenic territories in the developing skull vault, including the coronal suture. We show in addition that EphA4 is a Twist1 effector, and that loss of EphA signaling is causally linked to craniosynostosis, as suggested by our earlier identification of loss-of-function mutations in EFNA4 in humans with non-syndromic coronal synostosis (Merrill et al., 2006).

Both the penetrance and the severity of craniosynostosis increased significantly in Twist1+/−; EphA4+/− mutants compared with individual heterozygotes, demonstrating that Twist1 and EphA4 cooperate in the control of coronal suture development. That EphA4 was downregulated in Twist1 mutant sutures, whereas Twist1 expression was not altered in EphA4 mutants suggests that Twist1 is upstream of EphA4. An Efna2 mutant allele did not significantly enhance calvarial phenotypes caused by mutations in either Twist1 or EphA4. Efna2 is expressed in a pattern that overlaps substantially with Efna4 (Merrill et al., 2006); thus Efna2 and Efna4 may function redundantly. However, in our earlier screen of patients with non-syndromic craniosynostosis we did not detect mutations in Efna2 (Merrill et al., 2006). A definitive test of the roles of Efna2 and Efna4 in suture development will have to await an Efna4 knockout mouse.

The expansion of osteogenic marker gene expression into the mesenchyme of the coronal suture is associated with a reduction in P-Erk1/2 activity in the non-osteogenic, ephrin A-expressing layer outside the osteogenic layer. Total Erk activity is not affected, demonstrating that Twist1 and EphA4 control P-Erk1/2 signaling specifically. It is interesting that this change in P-Erk1/2 is in the cell layer in which osteogenic precursor cells migrate, and from which migratory cells are lost in Twist1-EphA4 combination mutants. Thus the phosphorylation status of Erk, which is known to be regulated by ephrin-Eph signaling (Elowe et al., 2001; Miao et al., 2001; Pasquale, 2008; Poliakov et al., 2004; Pratt and Kinch, 2002; Schmucker and Zipursky, 2001), may be related to the migratory properties of osteogenic precursor cells and to their association with this cell layer.

We note that our results on P-Erk1/2 levels are in apparent contrast with two recent findings. Yin et al. (Yin et al., 2008) found that an increase in P-Erk1/2 activity is associated with craniosynostosis in the Pro253Arg mutant of Fgfr2, which models Apert craniosynostosis; Connerney et al. (Connerney et al., 2008) showed that P-Erk1/2 is upregulated in sutures of Twist1 mutant mice. These results differ from ours in two important respects. First, both studies analyzed embryos at E16.5 or older, after the mis-migration/mixing events we document here have occurred. Second, both examined P-Erk1/2 activity at sites other than the ectocranial, EphA4-expressing layer. Yin et al. (Yin et al., 2008) in bone marrow cells and Connerney et al. (Connerney et al., 2008) in osteogenic fronts. These results, taken together with our findings, suggest that P-Erk signaling functions in two distinct processes, one at E15.5 or earlier, involving the partitioning of osteogenic cells between the EphA4-expressing layer and the osteogenic layer, the other at E16.5 or later involving the differentiation of osteogenic cells in the osteogenic layer or in the suture. The earlier process is positively regulated by Twist1, the later process negatively regulated.

Also associated with the expansion of osteogenic marker gene expression into sutural mesenchyme in individual and combination Twist1 and EphA4 mutants is a broadening of the distribution of P-Smad1/5/8-expressing cells and a reduction in their number. That Smad1/5/8 signaling is apparently reduced in craniosynostotic sutures may seem paradoxical given the general finding that Bmp signaling promotes osteogenesis. However, we note that in wild-type sutures, high levels of P-Smad1/5/8 are found in osteogenic fronts, which contain proliferative, ALP-positive cells, and lower levels are found in differentiating osteoblasts within the developing bone. Thus while the Bmp pathway has a well-documented positive role in osteogenesis, the transition from proliferative osteogenic cells of the osteogenic front to more differentiated osteoblasts in the mineralizing bone may actually entail a reduction in Bmp signaling. We note that two studies have reported increases in P-smad1/5/8 levels or Bmp activity in craniosynostotic sutures (Warren et al., 2003; Connerney et al., 2008). However, both focused on late-embryonic or postnatal stages, and in the case of Warren et al. (Warren et al., 2003), on a sagittal suture. Thus, as with P-Erk1/2 signaling, it is likely that these studies concern processes distinct from the boundary and migration defects we document here.

Wnt1-Cre/R26R and Mesp1-Cre/R26R markers provide complementary results demonstrating a defect in the neural crest mesoderm boundary at the coronal sutures of EphA4 and Twist1-EphA4 mutants. On the neural crest side, Wnt1-Cre-labeled cells are fated to become osteogenic cells of the frontal bone. On the mesoderm side, Mesp1-Cre-labeled cells are fated to become either sutural (non-osteogenic) cells or parietal bone osteogenic cells, or cells of the ectocranial layer. It is interesting that neither EphA4 nor any of the ephrin ligands we surveyed exhibit restricted expression at the neural crest-mesoderm boundary (Merrill et al., 2006) (A. Merrill and R.E.M., unpublished), suggesting that ephrin signaling controls boundary behavior not by regulating cell interactions at the immediate boundary, but by controlling the guidance or migratory behavior of osteogenic cells as they move apically from the frontal and parietal bone rudiments in the supraorbital ridge to the leading edges of the developing bone. We investigated this hypothesis by means of DiI labeling of embryos in vivo, followed by exo utero development of injected embryos. Iseki and colleagues used this technique to demonstrate that migratory cells contribute to the growing calvarial bones (Yoshida, 2005; Yoshida et al., 2008). We used this approach because of the lack of a satisfactory means of labeling and culturing calvarial rudiments in vitro in a way that mimics normal apical expansion of the frontal and parietal bones. This labeling technique enables us follow cells injected at E13.5 for periods of up to five days with no significant dilution of DiI. Moreover, development of injected embryos is normal.

The recent work of Yoshida et al. (Yoshida et al., 2008), together with our results (Fig. 8), demonstrates that DiI injected into the frontal or parietal bone rudiments labels osteogenic precursor cells. Our finding that cells labeled by injection of DiI into the parietal bone rudiment are present in the coronal suture of mutant mice strongly suggests that these are cells that would normally contribute to the parietal bone. Thus, from Wnt1-Cre and Mesp1-Cre lineage tracing, together with DiI labeling, we conclude that in Twist1-EphA4 mutant mice, osteogenic cells of neural crest and mesoderm origin cross a boundary between the osteogenic territories of the frontal and parietal bones and enter the coronal suture. We conclude further that the normal function of ephrin-Eph signaling is to target cells to appropriate sites at the coronal leading edge of the bone and ensure that they do not enter the coronal suture. How ephrin-Eph signaling achieves this remains unclear, although such signaling is known to guide cells by means of repulsive and attractive interactions (Arvanitis and Davy, 2008; Egea and Klein, 2007; Klein, 2004; Santiago and Erickson, 2002).

Twist1 mutant mice exhibit synostosis of the lambdoid suture as well as the coronal (H. Yen and R.E.M., unpublished observations). The lambdoid suture does not coincide with a major lineage boundary like the coronal, raising the question of the extent to which boundary defects are involved in lambdoid synostosis. Our Cre labeling and DiI labeling results suggest that it is not the neural crest-mesoderm boundary per se that is important in the development of coronal synostosis, but rather a defect in a boundary between osteogenic and non-osteogenic compartments. We suggest that such a mechanism may apply generally to the lambdoid and other sutures.

What is the role of mistargeting of osteogenic cells in the development of synostosis? That reduced dosage of the osteoblast determinant Runx2 can rescue the Twist1 synostosis phenotype (Bialek et al., 2004) suggests that inappropriate differentiation of osteogenic cells is part of the mechanism underlying synostosis in Twist1 mutants. Our present data show that in control embryos migratory osteogenic cells migrate apically along the ectocranial layer, ultimately reaching the leading edge of the bone. In mutant embryos, migratory osteogenic cells are excluded from the ectocranial layer, moving into the osteogenic layer and the prospective suture. Consequences of this include the broadening of ALP activity in the osteogenic layer, the presence of ALP-positive cells in the coronal at E14.5, and the ultimate formation of bone within the suture. We suggest that two mechanisms – aberrant migration and a change in osteogenic cell differentiation requiring Runx2 – work in sequence to produce synostosis. We propose that osteogenic cells from the frontal and parietal territories invade the coronal suture and signal normally non-osteogenic sutural cells to assume an osteogenic identity, thus producing synostosis.

Finally we note that our findings are consistent with the recent results of Yoshida et al. (Yoshida et al., 2008) in supporting the view that cell migration is a significant morphogenetic force in the patterned growth of the skull vault. Lana-Elola et al. (Lana-Elola et al., 2007) showed that only a small number of cells of the mesenchyme of the sagittal suture assume an osteogenic identity and are incorporated into the advancing parietal bone (Lana-Elola et al., 2007). However, inhibition of DNA synthesis slowed bone growth significantly, leading these authors to propose that proliferation of cells of the osteogenic fronts rather than recruitment of prepositioned mesenchyme is important for bone growth. Our results, together with those of Yoshida et al. (Yoshida et al., 2008) suggest that migration of osteoprogenitor cells from an area at the base of the growing rudiment also makes a major contribution to the apical expansion of calvarial bones. More precise identification of these progenitor cell populations, as well as an understanding of the processes that guide their migration and differentiation will illuminate the mechanisms that underlie the patterned growth of the skull as well as the pathophysiology of craniosynostosis.


We thank Drs Mamoru Ishii, Hai-Yun Yen, Amy E. Merrill, Inna Gitelman and Christopher Schafer for helpful discussions. This work was supported by NIH grants DE12941 and DE12450 (R.E.M.), a grant from the California Institute of Regenerative Medicine (T1-00004), and grant from the U.S.-Israel Binational Science Foundation (2001244). Deposited in PMC for release after 12 months.


  • Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem. 1992;40:1457–1463. [PubMed]
  • Arvanitis D, Davy A. Eph/ephrin signaling: networks. Genes Dev. 2008;22:416–429. [PubMed]
  • Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, et al. A twist code determines the onset of osteoblast differentiation. Dev Cell. 2004;6:423–435. [PubMed]
  • Carver EA, Oram KF, Gridley T. Craniosynostosis in Twist heterozygous mice: a model for Saethre-Chotzen syndrome. Anat Rec. 2002;268:90–92. [PubMed]
  • Chen L, Li D, Li C, Engel A, Deng CX. A Ser252Trp substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone. 2003;33:169–178. [PubMed]
  • Chen ZF, Behringer RR. twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev. 1995;9:686–699. [PubMed]
  • Cohen MM, Jr, MacLean RE. Should syndromes be defined phenotypically or molecularly? Resolution of the dilemma. Am J Med Genet. 1999;86:203–204. [PubMed]
  • Connerney J, Andreeva V, Leshem Y, Muentener C, Mercado MA, Spicer DB. Twist1 dimer selection regulates cranial suture patterning and fusion. Dev Dyn. 2006;235:1345–1357. [PubMed]
  • Connerney J, Andreeva V, Leshem Y, Mercado MA, Dowell K, Yang X, Lindner V, Friesel RE, Spicer DB. Twist1 homodimers enhance FGF responsiveness of the cranial sutures and promote suture closure. Dev Biol. 2008;318:323–334. [PMC free article] [PubMed]
  • Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP. Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. Curr Biol. 1998;8:1323–1326. [PubMed]
  • Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996;84:911–921. [PubMed]
  • Dottori M, Hartley L, Galea M, Paxinos G, Polizzotto M, Kilpatrick T, Bartlett PF, Murphy M, Kontgen F, Boyd AW. EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. Proc Natl Acad Sci USA. 1998;95:13248–13253. [PubMed]
  • Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol. 2007;17:230–238. [PubMed]
  • el Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, Bonaventure J. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet. 1997;15:42–46. [PubMed]
  • Elowe S, Holland SJ, Kulkarni S, Pawson T. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol. 2001;21:7429–7441. [PMC free article] [PubMed]
  • Feldheim DA, Kim YI, Bergemann AD, Frisen J, Barbacid M, Flanagan JG. Genetic analysis of ephrin-A2 and ephrin-A5 shows their requirement in multiple aspects of retinocollicular mapping. Neuron. 2000;25:563–574. [PubMed]
  • Guenou H, Kaabeche K, Mee SL, Marie PJ. A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome. Hum Mol Genet. 2005;14:1429–1439. [PubMed]
  • Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI, Garcia Delgado C, Gonzalez-Ramos M, Kline AD, Jabs EW. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet. 1997;15:36–41. [PubMed]
  • Ishii M, Merrill AE, Chan YS, Gitelman I, Rice DP, Sucov HM, Maxson RE., Jr Msx2 and Twist cooperatively control the development of the neural crest-derived skeletogenic mesenchyme of the murine skull vault. Development. 2003;130:6131–6142. [PubMed]
  • Jabs EW, Muller U, Li X, Ma L, Luo W, Haworth IS, Klisak I, Sparkes R, Warman ML, Mulliken JB, et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell. 1993;75:443–450. [PubMed]
  • Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, Mao JI, Charnas LR, Jackson CE, Jaye M. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet. 1994;8:275–279. [PubMed]
  • Jenkins D, Seelow D, Jehee FS, Perlyn CA, Alonso LG, Bueno DF, Donnai D, Josifova D, Mathijssen IM, Morton JE, et al. RAB23 mutations in Carpenter syndrome imply an unexpected role for hedgehog signaling in cranial-suture development and obesity. Am J Hum Genet. 2007;80:1162–1170. [PubMed]
  • Jiang X, Choudhary B, Merki E, Chien KR, Maxson RE, Sucov HM. Normal fate and altered function of the cardiac neural crest cell lineage in retinoic acid receptor mutant embryos. Mech Dev. 2002;117:115–122. [PubMed]
  • Johnson D, Iseki S, Wilkie AO, Morriss-Kay GM. Expression patterns of Twist and Fgfr1, -2 and -3 in the developing mouse coronal suture suggest a key role for twist in suture initiation and biogenesis. Mech Dev. 2000;91:341–345. [PubMed]
  • Kim HJ, Rice DP, Kettunen PJ, Thesleff I. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development. 1998;125:1241–1251. [PubMed]
  • Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr Opin Cell Biol. 2004;16:580–589. [PubMed]
  • Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002;3:475–486. [PubMed]
  • Lana-Elola E, Rice R, Grigoriadis AE, Rice DP. Cell fate specification during calvarial bone and suture development. Dev Biol. 2007;311:335–346. [PubMed]
  • Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem. 1999;75:566–577. [PubMed]
  • Liu B, Yu HM, Hsu W. Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation. Dev Biol. 2007;301:298–308. [PMC free article] [PubMed]
  • Marie PJ, Coffin JD, Hurley MM. FGF and FGFR signaling in chondrodysplasias and craniosynostosis. J Cell Biochem. 2005;96:888–896. [PubMed]
  • Martinez A, Soriano E. Functions of ephrin/Eph interactions in the development of the nervous system: emphasis on the hippocampal system. Brain Res Brain Res Rev. 2005;49:211–226. [PubMed]
  • Maxson R, Ishii M. The Bmp pathway in skull vault development. Front Oral Biol. 2008;12:197–208. [PubMed]
  • Merrill AE, Bochukova EG, Brugger SM, Ishii M, Pilz DT, Wall SA, Lyons KM, Wilkie AO, Maxson RE., Jr Cell mixing at a neural crest-mesoderm boundary and deficient ephrin-Eph signaling in the pathogenesis of craniosynostosis. Hum Mol Genet. 2006;15:1319–1328. [PubMed]
  • Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995;11:462–464. [PubMed]
  • Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol. 2001;3:527–530. [PubMed]
  • Muneoka K, Wanek N, Bryant SV. Mouse embryos develop normally exo utero. J Exp Zool. 1986;239:289–293. [PubMed]
  • Nieto MA, Gilardi-Hebenstreit P, Charnay P, Wilkinson DG. A receptor protein tyrosine kinase implicated in the segmental patterning of the hindbrain and mesoderm. Development. 1992;116:1137–1150. [PubMed]
  • Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002;16:1446–1465. [PubMed]
  • Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev. 2003;17:1429–1450. [PubMed]
  • Paratore C, Suter U, Sommer L. Embryonic gene expression resolved at the cellular level by fluorescence in situ hybridization. Histochem Cell Biol. 1999;111:435–443. [PubMed]
  • Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462–475. [PubMed]
  • Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133:38–52. [PubMed]
  • Poliakov A, Cotrina M, Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell. 2004;7:465–480. [PubMed]
  • Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene. 2002;21:7690–7699. [PubMed]
  • Rawlins JT, Opperman LA. Tgf-beta regulation of suture morphogenesis and growth. Front Oral Biol. 2008;12:178–196. [PubMed]
  • Rice DP, Kim HJ, Thesleff I. Apoptosis in murine calvarial bone and suture development. Eur J Oral Sci. 1999;107:265–275. [PubMed]
  • Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff I. Integration of FGF and TWIST in calvarial bone and suture development. Development. 2000;127:1845–1855. [PubMed]
  • Ryoo HM, Lee MH, Kim YJ. Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene. 2006;366:51–57. [PubMed]
  • Saga Y, Miyagawa-Tomita S, Takagi A, Kitajima S, Miyazaki J, Inoue T. MesP1 is expressed in the heart precursor cells and required for the formation of a single heart tube. Development. 1999;126:3437–3447. [PubMed]
  • Santiago A, Erickson CA. Ephrin-B ligands play a dual role in the control of neural crest cell migration. Development. 2002;129:3621–3632. [PubMed]
  • Schmucker D, Zipursky SL. Signaling downstream of Eph receptors and ephrin ligands. Cell. 2001;105:701–704. [PubMed]
  • Serbedzija GN, Bronner-Fraser M, Fraser SE. Vital dye analysis of cranial neural crest cell migration in the mouse embryo. Development. 1992;116:297–307. [PubMed]
  • Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet. 2007;39:1145–1150. [PubMed]
  • Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70–71. [PubMed]
  • Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004;15:419–433. [PubMed]
  • Vindis C, Cerretti DP, Daniel TO, Huynh-Do U. EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis. J Cell Biol. 2003;162:661–671. [PMC free article] [PubMed]
  • Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP, Richtsmeier JT, Leszl JM, Hill CA, et al. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development. 2005;132:3537–3548. [PubMed]
  • Wang X, Roy PJ, Holland SJ, Zhang LW, Culotti JG, Pawson T. Multiple ephrins control cell organization in C. elegans using kinase-dependent and -independent functions of the VAB-1 Eph receptor. Mol Cell. 1999;4:903–913. [PubMed]
  • Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT. The BMP antagonist noggin regulates cranial suture fusion. Nature. 2003;422:625–629. [PubMed]
  • Wilkie AO. Craniosynostosis: genes and mechanisms. Hum Mol Genet. 1997;6:1647–1656. [PubMed]
  • Wilkie AO, Morriss-Kay GM. Genetics of craniofacial development and malformation. Nat Rev Genet. 2001;2:458–468. [PubMed]
  • Wilkinson DG. Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci. 2001;2:155–164. [PubMed]
  • Yamaguchi TP, Rossant J. Fibroblast growth factors in mammalian development. Curr Opin Genet Dev. 1995;5:485–491. [PubMed]
  • Yang H, Wanner IB, Roper SD, Chaudhari N. An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. J Histochem Cytochem. 1999;47:431–446. [PubMed]
  • Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, et al. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone. 2008;42:631–643. [PubMed]
  • Yoshida T. Growth pattern of the frontal bone primordium and involvement of Bmps in this process. Kokubyo Gakkai Zasshi. 2005;72:19–27. [PubMed]
  • Yoshida T, Phylactou LA, Uney JB, Ishikawa I, Eto K, Iseki S. Twist is required for establishment of the mouse coronal suture. J Anat. 2005;206:437–444. [PubMed]
  • Yoshida T, Vivatbutsiri P, Morriss-Kay G, Saga Y, Iseki S. Cell lineage in mammalian craniofacial mesenchyme. Mech Dev. 2008;125:797–808. [PubMed]
  • Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. J Clin Invest. 2001;107:1153–1161. [PMC free article] [PubMed]
  • Yousfi M, Lasmoles F, El Ghouzzi V, Marie PJ. Twist haploinsufficiency in Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNFalpha expression and caspase-2 activation. Hum Mol Genet. 2002;11:359–369. [PubMed]
  • Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, Birchmeier W, Hsu W. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development. 2005;132:1995–2005. [PMC free article] [PubMed]
  • Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA, Ornitz DM. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development. 2003;130:3063–3074. [PubMed]